Skip to main content

Table 2 Selected drug repositioning candidates

From: Drug repositioning for enzyme modulator based on human metabolite-likeness

Target Enzyme
(Disease)a
Substrate Candidate drug
(Indicated Disease)
Similarity Reference
TYMS
(Cancer)
5,10-Methylene-
tetrahydrofolate
(Levo)leucovorin
(Osteosarcoma)
0.889 [44]
POLA1,POLB
(Leukemia)
dCTP Decitabine
(Myelodysplastic
Syndromes)
0.806 [45, 46]
DHFR
(Cancer)
(6S)-5,6,7,8-tetra-
hydrofolate(2-)
(Levo)leucovorin
(Osteosarcoma)
0.923 [44]
RRM1
(Leukemia)
CDP Cytarabine
(Leukemia)
0.841 [48]
DNMT1
(Leukemia)
Cytidine Gemcitabine
(Cancer)
0.875 [49]
IMPDH1/2
(Chronic Hepatitis C)
IMP Nelarabine
(Leukemia)
0.770 [50]
ENPP1
(Chronic Hepatitis C)
Deamino-NAD+ Vidarabine
(Herpes virus
infection)
0.781 [51]
ATIC
(Mesothlioma)
10-Formyl-
tetrahydrofolate
(Levo)leucovorin
(Osteosarcoma)
0.969 [44]
GART
(Mesothlioma)
10-Formyl-
tetrahydrofolate
(Levo)leucovorin
(Osteosarcoma)
0.969 [44]
NME1/2
(Cancer)
dCDP Decitabine
(Myelodysplastic
Syndromes)
0.806 [47]
XDH
(Hyperuricemia)
- - - -
  1. aDisease names are designated from the antimetabolite drug’s indicated disease